GKOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GKOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Glaukos's Total Liabilities for the quarter that ended in Dec. 2024 was $207.8 Mil. Glaukos's Total Assets for the quarter that ended in Dec. 2024 was $974.8 Mil. Therefore, Glaukos's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.21.
The historical data trend for Glaukos's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Liabilities-to-Assets | Get a 7-Day Free Trial |
![]() |
![]() |
0.34 | 0.44 | 0.47 | 0.51 | 0.21 |
Glaukos Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Liabilities-to-Assets | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.51 | 0.52 | 0.28 | 0.28 | 0.21 |
For the Medical Devices subindustry, Glaukos's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Glaukos's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Glaukos's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
Liabilities-to-Assets (A: Dec. 2024 ) | = | Total Liabilities | / | Total Assets |
= | 207.825 | / | 974.756 | |
= | 0.21 |
Glaukos's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as
Liabilities-to-Assets (Q: Dec. 2024 ) | = | Total Liabilities | / | Total Assets |
= | 207.825 | / | 974.756 | |
= | 0.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (NYSE:GKOS) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Glaukos's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Alex R. Thurman | officer: SVP & Chief Financial Officer | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Mark J Foley | director | ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588 |
Tomas Navratil | officer: Chief Development Officer | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Gilbert H Kliman | director | C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
Joseph E Gilliam | officer: CFO, SVP Corporate Development | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677 |
Marc Stapley | director | 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
Aimee S Weisner | director | ONE EDWARDS WAY, IRVINE CA 92614 |
Thomas William Burns | director, 10 percent owner, officer: Chief Executive Officer | C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
Denice Torres | director | 3 RABBIT RUN DRIVE, NEW HOPE PA 18938 |
Leana Wen | director | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Chris M. Calcaterra | officer: Chief Commercial Officer | C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
Link William J Phd | director, 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jonathan Silverstein | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Richard L Harrison | officer: Treasurer, CFO & Secretary | 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
From GuruFocus
By Business Wire • 02-20-2025
By Business Wire • 02-24-2025
By GuruFocus News • 01-23-2025
By GuruFocus News • 04-16-2025
By GuruFocus News • 03-13-2025
By GuruFocus News • 02-12-2025
By Business Wire • 01-23-2025
By GuruFocus News • 04-15-2025
By GuruFocus News • 02-20-2025
By GuruFocus News • 04-16-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.